FCCC LOGO Faculty Publications
Robinson MK , Alpaugh RK , Borghaei H
Naptumomab estafenatox: a new immunoconjugate
Expert Opinion on Biological Therapy. 2010 Feb;10(2) :273-279
PMID: ISI:000274499400011   
Back to previous list
Abstract
Importance of the field: New agents that specifically engage the immune system are being tested in a variety of malignancies. This review provides an overview of naptumomab, an immunotoxin, with encouraging clinical activity in Phase I trials. Areas covered in this review: This review examines the preclinical and the published clinical data with regards to naptumomab. What the reader will gain: This review provides the reader with an understanding of the mechanism of action, immunology, pharmacokinetics and clinical activity of this agent. Take home message: Naptumomab has a unique mechanism of action and appears to be an active agent in the treatment of refractory solid tumors such as renal cell carcinoma.
Notes
Robinson, Matthew K. Alpaugh, R. Katherine Borghaei, Hossein 31 Informa healthcare; telephone house, 69-77 paul street, london ec2a 4lq, england 555hj